IP Library Granted Patent US 7,141,044
Granted Patent B2
US 7,141,044 · App. 10/317,255 · Granted Nov 28, 2006

Alternate site gene therapy

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,141,044
App. No.
10/317,255
Granted
Nov 28, 2006
Kind
B2
Abstract

A method is described for performing gene therapy at an alternate site when it is undesirable or impossible to perform gene therapy at the injured or diseased region. A gene therapy composition is administered using a catheter adapted to deliver ultrasound to facilitate uptake of the gene therapy composition into one or more cells at the alternate site. The treated section may then be transplanted to another region of the body which is diseased or injured.

Claims (14)

1. A method for performing gene therapy on a selected section of a body lumen comprising:

placing within a selected section of the body lumen a catheter including one or more expandable members for occluding sections of the body lumen proximal and/or distal to the selected section;

occluding sections of the body lumen proximal and/or distal to the selected section of the body lumen;

delivering a gene therapy composition into the selected section of the body lumen;

delivering ultrasound to the selected section of the body lumen for a period of time in the presence of the gene therapy composition under conditions where the ultrasound causes cavitation of cells in the selected section; and

after delivering the gene therapy composition and ultrasound to the selected section of the body lumen, transplanting the selected section of the body lumen into another region of the body.

2. The method according to claim 1 wherein said selected section of the body lumen is highly vascularized.

3. The method according to claim 1 wherein said selected section of the body lumen is capable of anaerobic metabolism.

4. The method according to claim 1 wherein said selected section of the body lumen is highly vascularized and capable of anaerobic metabolism.

5. The method of claim 1 , wherein the selected section of the body lumen is a blood vessel of leg skeletal muscle.

6. The method of claim 1 , wherein the gene therapy composition comprises a gene operably linked to a promoter for expression in one or more cells within the selected section of the body lumen.

7. The method of claim 6 , wherein the gene produces a gene product which reduces the immune response to grafts.

8. The method of claim 6 , wherein the gene produces a gene product which blocks cell proliferation.

9. The method of claim 1 , wherein the gene therapy composition comprises an oligonucleotide.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2024
From: EKOS LLC
To: BOSTON SCIENTIFIC SCIMED, INC.
Reel/Frame 067042/0823 →
CHANGE OF NAME Recorded Apr 9, 2024
From: EKOS CORPORATION
To: EKOS LLC
Reel/Frame 067043/0077 →
RELEASE OF SECURITY INTEREST Recorded May 15, 2013
From: HERCULES TECHNOLOGY II, L.P.
To: EKOS CORPORATION
Reel/Frame 030421/0867 →
SECURITY AGREEMENT Recorded Jul 16, 2007
From: EKOS CORPORATION
To: HERCULES TECHNOLOGY II, L.P.
Reel/Frame 019550/0881 →